Tech Company Financing Transactions
Cytospire Therapeutics Funding Round
On 5/5/2026, Cytospire Therapeutics announced $83 million in Series A funding from 4BIO Capital, Abingworth and British Business Bank.
Transaction Overview
Company Name
Announced On
5/5/2026
Transaction Type
Venture Equity
Amount
$83,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to dvance its pipeline of first-in-class pan-gamma delta T cell engagers, including its lead programme, CYT X300, which is currently being advanced through IND-enabling preclinical studies and GMP manufacturing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
London Innovation Centre, 20 Water Street
London, E14 5GX
UK
London, E14 5GX
UK
Phone
Website
Email Address
Overview
Mission: To develop next generation ?d T cell engagers into impactful cancer therapies, enabled by our unique expertise and talented team. Our multispecific antibodies are designed to enhance and direct the power of key effector cells of the innate and adaptive immune system, providing a safer, more tailored alternative to CD3 based engagers. Purpose: To improve patients' lives by channelling our passion, science and curiosity into medicines that matter.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Peter Goodfellow
Chief Executive Officer
Natalie Mount
Chief Scientific Officer
James Legg
Chief Technical Officer
Mark Uden
VP - Bus. Development
Andrew Fadden
Browse more venture capital transactions:
Prev: 5/5/2026: Moritz venture capital transaction
Next: 5/5/2026: Village venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records on this site are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs